Literature DB >> 21113138

PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.

Laia Agell1, Silvia Hernández, Marta Salido, Silvia de Muga, Nuria Juanpere, Montserrat Arumí-Uria, Silvia Menendez, Marta Lorenzo, José A Lorente, Sergio Serrano, Josep Lloreta.   

Abstract

The phosphatidylinositol 3-kinase (PI3K)-AKT and RAS-MAPK pathways are deregulated in a wide range of human cancers by gain or loss of function in several of their components. Our purpose has been to identify genetic alterations in members of these pathways in prostate cancer. A total of 102 prostate tumors, 79 from prostate cancer alone (group G1) and 23 from bladder and prostate cancer patients (G2), are the subject of this study. In 20 of these 23, the bladder tumors were also analyzed. PIK3CA, KRAS, BRAF and AKT1 mutations were analyzed by direct sequencing, and BRAF also by pyrosequencing. PIK3CA quantitative mRNA expression and fluorescence in situ hybridization (FISH) gains were tested in 25 and 32 prostate tumors from both groups (G1 and G2), respectively. Immunohistochemistry for pAKT was performed in 55 prostate tumors. Of 25 prostate tumors, 10 (40%) had PIK3CA mRNA overexpression that was statistically associated with Gleason score ≥ 7 (P=0.018). PIK3CA copy gain was detected in 9 of 32 (28%) prostate tumors. Of 20 bladder tumors, 3 (15%) displayed mutations in PIK3CA, KRAS and AKT1, the corresponding prostate tumors being wt. We also detected a previously not reported PIK3CA polymorphism (IVS9+91) in two prostate tumors. In all, 56% of prostate tumors overexpressed pAKT. There is a statistical association (P<0.0001) of strong pAKT immunostaining with high Gleason score, and with PIK3CA alterations (mRNA overexpression and/or FISH gains). PIK3CA gene is deregulated by mRNA overexpression and DNA gain in ∼ 40 and 28% of prostate tumors, respectively. High-grade prostate tumors are associated with PIK3CA mRNA overexpression, but not with FISH status. PIK3CA, BRAF, KRAS and AKT1 mutations are very infrequent events in prostate tumors. However, PI3K signaling pathway is activated by PIK3CA FISH gain and/or mRNA overexpression, leading to an increased pAKT protein expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21113138     DOI: 10.1038/modpathol.2010.208

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

1.  Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2.

Authors:  Kangdong Liu; Chanmi Park; Shengqing Li; Ki Won Lee; Haidan Liu; Long He; Nak Kyun Soung; Jong Seog Ahn; Ann M Bode; Ziming Dong; Bo Yeon Kim; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-04-24       Impact factor: 4.944

2.  Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway.

Authors:  Rachana Garg; Jorge M Blando; Carlos J Perez; Martin C Abba; Fernando Benavides; Marcelo G Kazanietz
Journal:  Cell Rep       Date:  2017-04-11       Impact factor: 9.423

3.  miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA.

Authors:  Shengping Zhang; Jiarong Cai; Wenjun Xie; Hui Luo; Fei Yang
Journal:  Exp Ther Med       Date:  2018-06-12       Impact factor: 2.447

4.  Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.

Authors:  Christine M Barnett; Michael C Heinrich; Jeong Lim; Dylan Nelson; Carol Beadling; Andrea Warrick; Tanaya Neff; Celestia S Higano; Mark Garzotto; David Qian; Christopher L Corless; George V Thomas; Tomasz M Beer
Journal:  Clin Cancer Res       Date:  2013-12-18       Impact factor: 12.531

Review 5.  From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer.

Authors:  Chuan Yu; Kevin Hu; Daniel Nguyen; Zhu A Wang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

Review 6.  Cell mates: paracrine and stromal targets for prostate cancer therapy.

Authors:  Pavel Sluka; Ian D Davis
Journal:  Nat Rev Urol       Date:  2013-07-16       Impact factor: 14.432

7.  A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.

Authors:  Antonio Jimeno; Julie E Bauman; Charles Weissman; Douglas Adkins; Ian Schnadig; Patrice Beauregard; Daniel W Bowles; Alexander Spira; Benjamin Levy; Nagashree Seetharamu; Diana Hausman; Luke Walker; Charles M Rudin; Keisuke Shirai
Journal:  Oral Oncol       Date:  2015-01-13       Impact factor: 5.337

8.  Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas.

Authors:  Joanna Przybyl; Magdalena Kowalewska; Anna Quattrone; Barbara Dewaele; Vanessa Vanspauwen; Sushama Varma; Sujay Vennam; Aaron M Newman; Michal Swierniak; Elwira Bakuła-Zalewska; Janusz A Siedlecki; Mariusz Bidzinski; Jan Cools; Matt van de Rijn; Maria Debiec-Rychter
Journal:  JCI Insight       Date:  2017-06-02

9.  Nasoethmoidal Intestinal-Type Adenocarcinoma Treated with Cetuximab: Role of Liquid Biopsy and BEAMing in Predicting Response to Anti-Epidermal Growth Factor Receptor Therapy.

Authors:  Santiago Cabezas-Camarero; Virginia de la Orden García; Vanesa García-Barberán; Beatriz Mediero-Valeros; Ahmad Issa Subhi-Issa; Patricia Llovet García; Inmaculada Bando-Polaino; Salomé Merino Menéndez; Pedro Pérez-Segura; Eduardo Díaz-Rubio
Journal:  Oncologist       Date:  2019-01-02

10.  Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa).

Authors:  Meng Fu; Wei Zhang; Ling Shan; Jian Song; Donghao Shang; Jianming Ying; Jimao Zhao
Journal:  Virchows Arch       Date:  2014-03-05       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.